Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34041
Title: A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Austin Authors: Frentzas, Sophia;Gan, Hui K ;Cosman, Rasha;Coward, Jermaine;Tran, Ben;Millward, Michael;Zhou, Yiting;Wang, Wenjing;Xia, Dennis;Wang, Zhongmin Maxwell;Li, Baiyong;Xia, Michelle;Desai, Jayesh
Affiliation: Department of Medical Oncology, Monash Health, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
Medical Oncology
The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
ICON Cancer Centre, Brisbane, Australia; University of Queensland, Faculty of Medicine, Brisbane, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Linear Clinical Research, Nedland, Perth, Australia; School of Medicine, University of Western Australia, Perth, Australia.
Akeso Biopharma, Inc., Zhongshan, China.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
Issue Date: 21-Nov-2023
Date: 2023
Publication information: Cell Reports. Medicine 2023; 4(11)
Abstract: Simultaneous inhibition of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) with bispecific antibodies may improve efficacy over single-agent treatment while limiting toxicity. Cadonilimab is a humanized, bispecific antibody targeting PD-1 and CTLA-4. This is a phase 1 study of cadonilimab including dose escalation (n = 39) and dose expansion (n = 80). One dose-limiting toxicity event is observed, with the maximum tolerated dose not reached. 6 mg/kg cadonilimab once every 2 weeks is established as the recommended dose for future studies. The most common treatment-related adverse event is infusion-related reaction (18.5%), mostly grade 1/2 in severity. The incidences of any grade and grade ≥3 immune-related adverse events are 44.5% and 6.7%, respectively. The confirmed overall response rate is 13.4%, and the median duration of response is 12.9 months. Cadonilimab is well tolerated and showed promising efficacy in patients with advanced solid tumors. This study is registered with ClinicalTrials.gov: NCT03261011.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34041
DOI: 10.1016/j.xcrm.2023.101242
ORCID: 
Journal: Cell Reports. Medicine
Start page: 101242
PubMed URL: 37852261
ISSN: 2666-3791
Type: Journal Article
Subjects: CTLA-4
PD-1
advanced solid tumors
bispecific antibody
cadonilimab
immune checkpoint inhibitor
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Apr 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.